Regimen Reference Order

GYNE – trastuzumab + PACLitaxel + CARBOplatin (endometrial)

ARIA: GYNE - [trastuzumab + PACL + CARBO]

Planned Course: trastuzumab + PACLitaxel + CARBOplatin every 21 days for 6 cycles, followed by trastuzumab every 21 days until disease progression or unacceptable toxicity

Indication for Use: Uterine Serous Cancer Recurrent/Metastatic HER2 positive

CVAD: At Provider's Discretion

Proceed with treatment if:

Cycle 1

ANC equal to or greater than 1.5 x 10⁹/L AND Platelets equal to or greater than 100 x 10⁹/L Cycles 2 to 6
ANC equal to or greater than 1.2 x 10⁹/L AND Platelets equal to or greater than 75 x 10⁹/L trastuzumab Maintenance
Blood work at provider's discretion; not required to proceed with treatment

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
	No	ot Applicable		

Treatment Regimen GYNE – trastuzumab + PACLitaxel + CARBOplatin (endometrial)

Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
Cycles 1 to 6 – trastuzumab + PACLitaxel + CARBOplatin				
Day 1				
trastuzumab (brand name specific)	Cycle 1 8 mg/kg Loading dose	IV in normal saline 250 mL over 90 minutes *Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order *Nursing Alert: PACLitaxel infusion begins after observation period is complete		
	Cycles 2 to 6 6 mg/kg	IV in normal saline 250 mL over 30 minutes *Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order		
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel		



e-chemotherapy es pre-chemotherapy ne 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel starts 1 hour after completion of
ne 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel starts 1 hour after completion of
PACLitaxel starts 1 hour after completion of
infusion
ng PACLitaxel
ne 500 mL over 3 hours, following the action at the action of the action of the action of the second s
ster at 100 mL/hour for 15 minutes, then
ster remaining volume over 2 hours and 45 s
ags and non-DEHP administration sets with 0.2 ilter
Gently invert bag 8 to 10 times immediately prior n of PACLitaxel to evenly distribute the drug
nL over 30 minutes
lays
ne 250 mL over 30 minutes
rand name on prescription label (indicated in scription label) matches prescribed order
ali b

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Cardiac monitoring

• Left Ventricular Ejection Fraction (LVEF) at baseline and every 4 cycles (i.e. 12 weeks) as per Physician Orders

Cycles 1 to 6

• CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin as per Physician Orders

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after trastuzumab infusion (first dose). Full vital signs after observation period is complete. PACLitaxel infusion begins after observation period is complete
- No observation period required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not



ADULT

Cycles 2 to 6

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after trastuzumab or PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

trastuzumab Maintenance

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
Cycles 1 to 6 – trastuzumab + PACLitaxel + CARBOplatin			
aprepitant	80 mg	Orally once daily on Days 2 and 3	
dexamethasone	8 mg	Orally once daily on Days 2 and 3	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	
trastuzumab Maintenance			
None required			

DISCHARGE INSTRUCTIONS

Cycles 1 to 6

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy


trastuzumab Maintenance

• Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge

ADDITIONAL INFORMATION

- Reassess trastuzumab dose with significant weight changes
- trastuzumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after trastuzumab. Ensure prescription label matches the brand name on prescribed order
- PACLitaxel may cause progressive, irreversible neuropathy
- CARBOplatin dose considerations:
 - The ARIA regimen is built with an AUC of 5
 - At the discretion of the Gyne-Oncologist, CARBOplatin dose may be increased to AUC 6
 - o CCMB Gynecological DSG uses a maximum CARBOplatin dose of 900 mg for this regimen
 - CCMB Gynecological DSG uses **actual body weight** to calculate GFR
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber





AUC = Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation may not be appropriate for some patient populations (for example, acute renal failure).

